medigraphic.com

2015, Número S2

<< Anterior Siguiente >>

Rev Med Inst Mex Seguro Soc 2015; 53 (S2)


Prevalencia de genotipos de VPH en México y en el mundo detectados mediante Linear Array

Flores-Miramontes MG, Torres-Reyes LA, Aguilar-Lemarroy A, Vallejo-Ruíz V, Piña-Sánchez P, Cortés-Gutiérrez E, Reyes-Leyva J, Jave-Suárez LF

Idioma: Español
Referencias bibliográficas: 35
Paginas: 122-130
Archivo PDF: 410.01 Kb.


RESUMEN

La infección por el virus de papiloma humano (VPH) es el principal factor asociado al desarrollo de cáncer cervicouterino (CaCU). Conocer la prevalencia de los diversos VPH en distintas etapas del desarrollo del CaCU es relevante para determinar los VPH de riesgo oncogénico, establecer el desarrollo de estrategias de tamizaje y la evaluación de programas de prevención, así como para el diseño de vacunas. El presente trabajo es un metaanálisis sobre prevalencia de VPH a nivel mundial y en México de estudios que hayan utilizado el Linear Array® HPV Genotyping Test como prueba diagnóstica (prueba comercial que a la fecha identifica la mayor cantidad de genotipos de VPH en una sola muestra), en ADN de raspados cervicales de mujeres con diagnóstico citológico normal, con lesión intraepitelial escamosa de bajo grado (LIEBG), con lesión intraepitelial escamosa de alto grado (LIEAG) y con CaCU. En mujeres con este tipo de cáncer, los genotipos más prevalentes después de los VPH-16 y -18 varían dependiendo de la región geográfica, lo que soporta la necesidad de desarrollar estrategias de detección y prevención acordes a las características de la población.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Zur Hausen H. Papillomaviruses in the causation of human cancers - a brief historical account. Virology. 2009;384(2):260-5.

  2. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum. 2012;100(Pt B):1-441.

  3. De Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B. et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010;11(11):1048-56.

  4. Peralta-Rodriguez R, Romero-Morelos P, Villegas- Ruíz V, Mendoza-Rodríguez M, Taniguchi-Ponciano K, Gonzalez-Yebra B. et al. Prevalence of human papillomavirus in the cervical epithelium of Mexican women: meta-analysis. Infect Agent Cancer. 2012;7(1):34.

  5. Koshiol J, Dunn ST, Walker JL, Zuna RE, Schiffman M, Sherman ME et al. Reproducibility of linear array for human papillomavirus genotyping. J Clin Microbiol. 2013;51(2):625-8.

  6. 6 D e Sanjose S, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N. et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis. Lancet Infect Dis. 2007;7(7):453-9.

  7. Lazcano-Ponce E, Herrero R, Muñoz N, Cruz A, Shah KV, Alonso P. et al. Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer. 2001;91(3):412-20.

  8. Vidal AC, Murphy SK, Hernández BY, Vasquez B, Bartlett JA, Oneko O et al. Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women. Infect Agent Cancer. 2011;6(1):20.

  9. Fröberg M, Johansson B, Hjerpe A, Andersson S. Human papillomavirus ‘reflex’ testing as a screening method in cases of minor cytological abnormalities. Br J Cancer. 2008;99(4):563-8.

  10. Marais DJ, Passmore JAS, Denny L, Sampson C, Allan BR, Williamson AL. Cervical and oral human papillomavirus types in HIV‐1 positive and negative women with cervical disease in South Africa. J Med Virol. 2008;80(6):953-9.

  11. Vaccarella S, Plummer M, Franceschi S, Gravitt P, Papenfuss M, Smith D. et al. Clustering of human papillomavirus (HPV) types in the male genital tract: the HPV in men (HIM) study. J Infect Dis. 2011;204(10):1500-4.

  12. Ferreccio C, Corvalán A, Margozzini P, Viviani P, González C, Aguilera X. et al. Baseline assessment of prevalence and geographical distribution of HPV types in Chile using self-collected vaginal samples. BMC Public Health. 2008;8(1):78. doi: 10.1186/1471-2458-8-78.

  13. Shaltout MF, Sallam HN, Abou Seeda M, Moiety F, Hemeda H, Ibrahim A. et al. Prevalence and type distribution of human papillomavirus among women older than 18 years in Egypt: a multicenter, observational study. Int J Infect Dis. 2014;29(2)26-31.

  14. Demir ET, Ceyhan M, Simsek M, Gunduz T, Arlier S, Aytac R. et al. The prevalence of different HPV types in Turkish women with a normal Pap smear. J Med Virol 2012;84(8):1242-7.

  15. Castle PE, Gravitt PE, Solomon D, Wheeler CM, Schiffman M. Comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low-grade squamous intraepithelial lesion triage study. J Clin Microbiol. 2008;46(1):109-17.

  16. Coutlée F, Ratnam S, Ramanakumar AV, Insinga RR, Bentley J, Escott N. et al. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada. J Med Virol. 2011;83(6):1034-41.

  17. Wentzensen N, Wilson LE, Wheeler CM, Carreon JD, Gravitt PE, Schiffman M et al. Hierarchical clustering of human papilloma virus genotype patterns in the ASCUS-LSIL triage study. Cancer Res. 2010;70(21):8578-86.

  18. Halfon P, Lindemann ML, Raimondo A, Ravet S, Camus C, Khiri H. et al. HPV genotype distribution according to severity of cervical neoplasia using the Digene HPV genotyping LQ test. Arch Virol. 2013;158(6):1143-9.

  19. Stevens MP, Garland SM, Tan JH, Quinn MA, Petersen RW, Tabrizi SN. HPV genotype prevalence in women with abnormal pap smears in Melbourne, Australia. J Med Virol. 2009;81(7):1283-91.

  20. Mateos Lindemann ML, Sánchez Calvo JM, Chacón de Antonio J, Sanz I, Díaz E, Rubio MD et al. Prevalence and distribution of high-risk genotypes of HPV in women with severe cervical lesions in Madrid, Spain: Importance of detecting genotype 16 and other highrisk genotypes. Adv Prev Med. 2011;2011:269468. doi: 10.4061/2011/269468. Epub 2010 Sep 27.

  21. Dobec M, Bannwart F, Kilgus S, Kaeppeli F, Cassinotti P. Human papillomavirus infection among women with cytological abnormalities in Switzerland investigated by an automated linear array genotyping test. J Med Virol. 2011;83(8):1370-6.

  22. Pista A, de Oliveira CF, Lopes C, Cunha MJ. Human papillomavirus type distribution in cervical intraepithelial neoplasia grade 2/3 and cervical cancer in Portugal: a CLEOPATRE II Study. Int J Gynecol Cancer: 2013;23(3):500-6.

  23. Anderson L, O'Rorke M, Jamison J, Wilson R, Gavin A. Prevalence of human papillomavirus in women attending cervical screening in the UK and Ireland: new data from northern Ireland and a systematic review and meta-analysis. J Med Virol. 2013;85(2):295-308.

  24. Louvanto K, Rintala MA, Syrjanen KJ, Grenman SE, Syrjanen SM. Incident cervical infections with highand low-risk human papillomavirus (HPV) infections among mothers in the prospective Finnish Family HPV Study. BMC Infect Dis. 2011;11:179.

  25. Dutra I, Santos MR, Soares M, Couto AR, Bruges- Armas M, Teixeira F. et al. Characterisation of human papillomavirus (HPV) genotypes in the Azorean population, Terceira island. Infect Agent Cancer. 2008; 3:6.

  26. Nielsen A, Iftner T, Norgaard M, Munk C, Junge J, Kjaer SK. The importance of low-risk HPV infection for the risk of abnormal cervical cytology/histology in more than 40 000 Danish women. Sex Transm Infect. 2012;88(8):627-32.

  27. Sjoeborg KD, Trope A, Lie AK, Jonassen CM, Steinbakk M, Hansen M et al. HPV genotype distribution according to severity of cervical neoplasia. Gynecol Oncol. 2010;118(1):29-34.

  28. Wentzensen N, Schiffman M, Dunn T, Zuna RE, Gold MA, Allen RA. et al. Multiple human papillomavirus genotype infections in cervical cancer progression in the study to understand cervical cancer early endpoints and determinants. Int J Cancer. 2009;125(9):2151-8.

  29. Hariri S, Steinau M, Rinas A, Gargano JW, Ludema C, Unger ER et al. HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001–2006. PLoS One. 2012;7(3):e34044. doi: 10.1371/journal.pone.0034044. Epub 2012 Mar 29.

  30. Siriaunkgul S, Suwiwat S, Settakorn J, Khunamornpong S, Tungsinmunkong K, Boonthum A. et al. HPV genotyping in cervical cancer in Northern Thailand: adapting the linear array HPV assay for use on paraffin-embedded tissue. Gynecologic Oncology. 2008;108(3):555-60.

  31. Wong OG, Lo CK, Chow JN, Tsun OK, Szeto E, Liu SS et al. Comparison of the GenoFlow human papillomavirus (HPV) test and the Linear Array assay for HPV screening in an Asian population. J Clin Microbiol. 2012;50(5):1691-7.

  32. Zhang T, Xu Y, Qiao L, Wang Y, Wu X, Fan D. et al. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine. 2010;28(19):3479-87.

  33. González-Losa Mdel R, Rosado-Lopez I, Valdez- González N, Puerto-Solis M. High prevalence of human papillomavirus type 58 in Mexican colposcopy patients. J Clin Virol. 2004;29(3):202-5.

  34. De Oliveira CM, Fregnani JH, Carvalho JP, Longatto- Filho A, Levi JE. Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil. BMC Cancer. 2013 Jul 24;13:357. doi: 10.1186/1471-2407-13-357.

  35. Fu L, Van Doorslaer K, Chen Z, Ristriani T, Masson M, Trave G . e t a l. D egradation o f p 53 b y h uman Alphapapillomavirus E6 proteins shows a stronger correlation with phylogeny than oncogenicity. PLoS One. 2010 Sep 17;5(9). pii: e12816. doi: 10.1371/journal. pone.0012816.




2020     |     www.medigraphic.com